AbbVie unveils Venclexta data that scored lightning-fast leukemia combination nod

AbbVie's Venclexta-Gazyva combination joins its Imbruvica in the first-line CLL setting. (AbbVie)

CHICAGO—Last month, partners AbbVie and Roche nabbed a speedy approval for Venclexta and Gazyva in chronic lymphocytic leukemia (CLL). And Tuesday, they rolled out the data that helped get them to the finish line.

A phase 3 study presented at the American Society of Clinical Oncology annual meeting showed that in previously untreated patients with both CLL and other medical conditions, the combination cut the risk of disease progression or death by 65% versus Gazyva and chlorambucil, a regimen commonly used to treat that population.

RELATED: AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

At the two-year mark, 88.2% of patients in the Venclexta arm hadn’t seen their disease worsen, compared with 64.1% of patients on the standard-of-care combination.

Those results apparently impressed regulators, who green-lighted the combination in mid-May under the FDA’s new Real-Time Oncology Review pilot. The program allows regulators to begin going through data before a company officially submits its complete application, and it yielded a go-ahead for the drugmakers less than three months after their official filing date, said Rod Humerickhouse, M.D., Ph.D., asset strategy leader at AbbVie.

“I think it is a tremendous step forward for the patient that the FDA is committed to identifying breakthrough therapies and getting them out to patients as quickly as possible,” he said.

RELATED: ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'

Meanwhile, thanks to the approval, AbbVie now has two chemo-free options to offer patients in the front-line setting. The Venclexta-Gazyva pairing joins Imbruvica, the Johnson & Johnson-shared blockbuster that AbbVie paid big money to access when it bought out Pharmacyclics for $21 billion back in 2015.

That drug has continued to post impressive results of its own, including six-year data that debuted at ASCO. And with two choices now for doctors and patients, AbbVie execs expect to see chemo’s role in the disease diminish.

“With two new targeted agents that AbbVie has brought forward, it’s really changed the whole treatment paradigm,” Humerickhouse said. “Not only are you having treatment success … you’re doing that with significantly reduced toxicities.”

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.